Catalyst Event
Moderna Inc (MRNA) · Other
From KEDI Global Longevity Bio Index (KGLB)
6/1/2026, 12:00:00 AM
Moderna and Merck to present positive 5-year follow-up data from the Phase 2b study of their personalized cancer vaccine, intismeran autogene, at the 2026 ASCO Annual Meeting on June 1, 2026, showing a 49% reduction in risk; High importance due to the significant 49% reduction in recurrence risk, likely causing ≥10% price impact, scheduled.
Korean Translation
2026년 6월 1일 미국임상종양픙회(ASCO) 연례회의에서 모더나와 머크의 개인 맞춤형 암 백신 인티스메란 오토진 2b상 5년 추적 관찰 데이터 발표 및 49% 위험 감소 결과 발표; 49%의 재발 위험 감소라는 획기적 결과로 10% 이상의 주가 영향이 예상되어 중요도를 'High'로 설정함, 예정됨.
Related Recent Events
Exelixis Inc (EXEL) · Other
U.S. FDA PDUFA target action date for zanzalintinib (December 3, 2026) is a potential first approval for a major new franchise; >10% price impact is estimated, scheduled.
12/3/2026, 12:00:00 AM
Bristol-Myers Squibb Co (BMY) · Other
The U.S. FDA set a PDUFA target action date for iberdomide on 2026-08-17; importance is Low as the setting of a PDUFA date is a procedural event with minor price impact.
8/17/2026, 12:00:00 AM
Moderna Inc (MRNA) · Other
FDA Prescription Drug User Fee Act (PDUFA) target action date for its seasonal flu vaccine (mRNA-1010) on August 5, 2026; Medium importance as PDUFA dates are major catalysts for biotech stocks, scheduled.
8/5/2026, 12:00:00 AM
Pfizer Inc (PFE) · Earnings Release
Next quarterly earnings for Q2 2026 are expected to be announced on August 4, 2026; medium impact estimated based on historical volatility during earnings releases, expected.
8/4/2026, 12:00:00 AM
Sanofi (SNY) · Earnings Release
Sanofi's Q2 2026 earnings results release on July 30, 2026, is expected to have a Medium impact as earnings typically drive 5-10% price volatility scheduled.
7/30/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM